Precision Radiation Oncology最新文献_第3页

Clinical outcomes of multisite moderate to high dose radiotherapy for patients with metastatic melanoma 转移性黑色素瘤患者接受多部位中高剂量放射治疗的临床疗效

Precision Radiation Oncology Pub Date : 2024-03-24 DOI: 10.1002/pro6.1224

Kelly H. Li, P. Cheung, Teresa M. Petrella, Liying Zhang, I. Poon, I. Menjak

{"title":"Clinical outcomes of multisite moderate to high dose radiotherapy for patients with metastatic melanoma","authors":"Kelly H. Li, P. Cheung, Teresa M. Petrella, Liying Zhang, I. Poon, I. Menjak","doi":"10.1002/pro6.1224","DOIUrl":"https://doi.org/10.1002/pro6.1224","url":null,"abstract":"This study aimed to summarize the clinical outcomes of patients with metastatic melanoma who received high‐dose radiation prior to or during systemic therapy at a single academic institution.We identified patients with metastatic melanoma who underwent high‐dose radiation therapy (HDRT) for extracranial metastases prior to or during systemic therapy from 2010 to 2018. Treatment indications included oligometastases, oligoprogression, and local control. Using the Kaplan‐Meier method, we plotted overall survival (OS), progression‐free survival‐1 (PFS1), and PFS2. Competing risk analysis determined the cumulative incidence of local failure (LF) and the time to start or change systemic therapy (SCST). Univariate and multivariable analyses were used to identify predictive factors.We analyzed 34 patients with 79 lesions, with a median follow‐up of 17.4 months. Sixty‐eight percent of patients received systemic therapy after the first HDRT. The median OS was 22 months, with brain metastases before HDRT being a significant predictor in multivariable analysis. The median PFS1 for first‐line HDRT was 4.1 months, and the median PFS2 was 3.9 months. Rates of LF were 10.3% at 12 months and 11.7% at 24 months. The incidence of SCST following HDRT was 59.8% at 12 months and 76.1% at 24 months, with radiation targeted at the lung associated with a lower incidence of SCST.HDRT for treating metastatic lesions in melanoma demonstrated excellent local control and may play a role in delaying SCST. Additional courses of HDRT may provide cumulative benefits.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140385558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic radiotherapy: An educational narrative review 立体定向放射治疗：教育叙事回顾

Precision Radiation Oncology Pub Date : 2024-03-21 DOI: 10.1002/pro6.1222

A. Khan, Syed Furqan Ahmad Hashmi, Benjamin Li, Fatima Shaukat, Yumna Ahmed, Mahmud Al‐Feshawi, Iqbal Al‐Amri, Rashid Bashir, Furhan Altaf, Sercan Yilmaz, Jamsari Khalid, Z. A. Mandhari, Nadeem Pervez, Salim Chaib Rassou, L. Mula-Hussain

{"title":"Stereotactic radiotherapy: An educational narrative review","authors":"A. Khan, Syed Furqan Ahmad Hashmi, Benjamin Li, Fatima Shaukat, Yumna Ahmed, Mahmud Al‐Feshawi, Iqbal Al‐Amri, Rashid Bashir, Furhan Altaf, Sercan Yilmaz, Jamsari Khalid, Z. A. Mandhari, Nadeem Pervez, Salim Chaib Rassou, L. Mula-Hussain","doi":"10.1002/pro6.1222","DOIUrl":"https://doi.org/10.1002/pro6.1222","url":null,"abstract":"Stereotactic radiotherapy is a term collectively used to describe the radiation treatment techniques that allow for the delivery of highly precise ionizing radiation. It is usually a high dose per session in single or few fractions. This treatment approach has been in medical use for over six decades and has primarily evolved in the last two decades. Many patients benefit from this unique non‐conventional radiotherapy approach. Its indications include various malignant, benign and functional problems in cranial and body sites. This technique is not widespread in developing countries compared to developed countries. This work is an educational narrative review for learners in radiation oncology. We aim to share the knowledge of this practice to improve precision radiation oncology globally. This review summarizes the basics of stereotactic radiotherapy, the technical prerequisites, the clinical considerations, the practical recommendations and the learning points from each site‐specific region.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140222121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical application of high‐LET radiotherapy combined with immunotherapy in malignant tumors 高放疗联合免疫疗法在恶性肿瘤中的临床应用

Precision Radiation Oncology Pub Date : 2024-03-20 DOI: 10.1002/pro6.1225

Kexin Meng, Haijun Lu

引用次数: 0

Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer 老年局限期小细胞肺癌患者的胸腔放疗时机和预后因素

Precision Radiation Oncology Pub Date : 2024-03-14 DOI: 10.1002/pro6.1223

Huan Zhao, Yue Qi, Lanfang Zhang, Meng Xing, Fujun Yang

{"title":"Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer","authors":"Huan Zhao, Yue Qi, Lanfang Zhang, Meng Xing, Fujun Yang","doi":"10.1002/pro6.1223","DOIUrl":"https://doi.org/10.1002/pro6.1223","url":null,"abstract":"This study assessed the outcomes of elderly patients with limited‐stage small cell lung cancer (LS‐SCLC), which may be linked to the timing of thoracic radiotherapy (TRT) following chemotherapy.Elderly patients (n = 78) with LS‐SCLC were divided into three groups depending on the timing of radiotherapy. The patients in the TRT group were stratified into early (TRT after 1–2 cycles of chemotherapy, n = 29), medium‐term (TRT after 3–4 cycles of chemotherapy, n = 33), and late (TRT after 5–6 cycles of chemotherapy, n = 16) TRT groups. The overall survival (OS) and progression‐free survival (PFS) were assessed and compared.The medium‐term TRT group demonstrated significantly longer mPFS (20.12 months) and better mOS (35.97 months) than those in the other groups (PFS: P = 0.021;OS: P = 0.035). A pairwise comparison of the three groups revealed that those who received medium‐term TRT exhibited significantly improved PFS than the early (mPFS: 20.12 vs. 10.36 mouths, P = 0.018) and late (mPFS: 20.12 vs. 9.17 months, P = 0.016) TRT. The medium‐term TRT group demonstrated significantly improved OS than the early TRT (mOS: 35.97 vs. 25.22 months, P = 0.007) but not in comparison with the late TRT (mOS: 35.97 vs. 21.63 months, P = 0.100).In elderly patients with LS‐SCLC, the addition of TRT after 3–4 cycles of chemotherapy appears to be a viable and potentially beneficial treatment approach.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"13 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140244400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiation therapy for clinically diagnosed early-stage non-small cell lung cancer: Importance of accurate CT interpretation by experts. 立体定向体放射治疗临床诊断的早期非小细胞肺癌：专家准确CT解读的重要性。

Precision Radiation Oncology Pub Date : 2024-03-10 eCollection Date: 2024-03-01 DOI: 10.1002/pro6.1220

Daisuke Nakamura, Koichi Honda, Takuya Yamazaki, Hideyuki Hayashi, Shin Tsutsui, Aya Fukushima, Sumihisa Honda, Masataka Uetani, Kazuto Ashizawa

{"title":"Stereotactic body radiation therapy for clinically diagnosed early-stage non-small cell lung cancer: Importance of accurate CT interpretation by experts.","authors":"Daisuke Nakamura, Koichi Honda, Takuya Yamazaki, Hideyuki Hayashi, Shin Tsutsui, Aya Fukushima, Sumihisa Honda, Masataka Uetani, Kazuto Ashizawa","doi":"10.1002/pro6.1220","DOIUrl":"https://doi.org/10.1002/pro6.1220","url":null,"abstract":"Introduction: This study evaluated the clinical outcomes of stereotactic body radiotherapy (SBRT) for both pathologically diagnosed (PD) and clinically diagnosed (CD) early-stage non-small cell lung cancer (NSCLC) and explored the significance of accurate expert computed tomography (CT) interpretation.Methods: We retrospectively analyzed 95 patients with early-stage NSCLC who received SBRT at our institution. Patients were classified into CD and PD groups. Two chest radiologists retrospectively interpreted the pre-SBRT CT images to determine the tumor subtype and probability of malignancy (PM). Clinical findings, CT features, and treatment outcomes were compared between the two groups. The survival rate of the CD group was analyzed separately according to the PM grade.Results: Median overall survival for the CD and PD groups was 6.0 and 5.4 years (P = 0.57), respectively. Median cause-specific survival was 10.2 years in the CD group and not reached in the PD group (P = 0.76). In the CD group, lung cancer mortality was lower in the low PM group (25% [1 of 4]) than in the high PM group (47.4% [9 of 19]).Conclusion: It may be desirable to evaluate the PM of the nodule using expert CT interpretation to decide whether SBRT is indicated in CD early-stage NSCLC.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 1","pages":"30-36"},"PeriodicalIF":0.0,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lymphocytopenia following adjuvant radiotherapy for breast cancer 乳腺癌辅助放疗后的淋巴细胞减少症

Precision Radiation Oncology Pub Date : 2024-02-29 DOI: 10.1002/pro6.1221

K. Takeda, R. Umezawa, Takaya Yamamoto, N. Takahashi, Yu Suzuki, K. Kishida, So Omata, K. Jingu

{"title":"Lymphocytopenia following adjuvant radiotherapy for breast cancer","authors":"K. Takeda, R. Umezawa, Takaya Yamamoto, N. Takahashi, Yu Suzuki, K. Kishida, So Omata, K. Jingu","doi":"10.1002/pro6.1221","DOIUrl":"https://doi.org/10.1002/pro6.1221","url":null,"abstract":"We retrospectively analyzed breast cancer patients who received adjuvant radiotherapy to determine the incidence of lymphocytopenia and its risk factors.We reviewed 812 patients with breast cancer who received postoperative radiotherapy. Patients were divided into two groups based on the use of chemotherapy, and a generalized linear regression model was used to explore predictive factors for grade 2 or higher lymphocytopenia. We also examined the effect of lymphocytopenia on overall survival.Grade 2 or higher lymphocytopenia was observed in 19.4% of patients who did not receive chemotherapy and 45.1% of patients who received chemotherapy. In multivariate analysis, bilateral disease, regional lymph node irradiation, and baseline lymphocytopenia were associated with lymphocytopenia in patients who did not receive cytotoxic chemotherapy. Regional lymph node irradiation, baseline lymphocytopenia, use of antimetabolites, and use of molecular‐targeted agents were associated with lymphocytopenia in patients treated with chemotherapy. In the survival analysis, lymphocytopenia was associated with worse overall survival only in patients treated with cytotoxic chemotherapy (p = 0.039), and not in patients who did not receive chemotherapy (p = 0.77).The analysis revealed the incidence and risk factors of lymphocytopenia after postoperative radiotherapy in patients with breast cancer.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"2014 29","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140416215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Guidelines for the Prevention and Treatment of Radiation‐induced Bladder Injury 预防和治疗辐射所致膀胱损伤的临床指南

Precision Radiation Oncology Pub Date : 2024-02-08 DOI: 10.1002/pro6.1215

Weiping Wang, Fuquan Zhang, Shuanghu Yuan

引用次数: 0

Clinical Guidelines for the Prevention and Treatment of Radiation‐induced Bladder Injury 预防和治疗辐射所致膀胱损伤的临床指南

Precision Radiation Oncology Pub Date : 2024-02-08 DOI: 10.1002/pro6.1215

Weiping Wang, Fuquan Zhang, Shuanghu Yuan

引用次数: 0

Precision radiotherapy for nasopharyngeal carcinoma 鼻咽癌的精确放射治疗

Precision Radiation Oncology Pub Date : 2024-01-30 DOI: 10.1002/pro6.1219

Zhenyu Zhang, Xiangzhou Chen, Taize Yuan